Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +40.55%
#3 CoW Protocol CoW Protocol +36.27%
#4 Humanity Humanity +25.26%
#5 Enso Enso +22.42%
#6 Tutorial Tutorial +22.06%
#7 Walrus Walrus +21.16%
#8 BOOK OF MEME BOOK OF MEME +18.05%
#9 Codatta Codatta +15.02%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Rangering i aksjer #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Aksjekurs
$0.6
Sist synkronisert: 2024-08-14
Markedsverdi
$2.09M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
SG
Handel ASLAN Pharmaceuticals Limited (ASLN)

Kategori

Healthcare
Inntekter for ASLAN Pharmaceuticals Limited (ASLN)
Inntekter i Mar 2024 TTM: $12.00M
Ifølge de nyeste økonomiske rapportene til ASLAN Pharmaceuticals Limited er selskapets nåværende inntekter (TTM) $12.00M. I 2022 hadde selskapet inntekter på 0.00 lik inntektene i 2021, som var 0.00. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for ASLAN Pharmaceuticals Limited fra 2014 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $12.00M 0.00%
2023 $12.00M 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $3.00M 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 $11.49M 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 105,102.50%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 50,077.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 84,156.56%
BE